Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker

In an earlier phase I study, we reported that the maximal tolerated dose (MTD) of prochlorperazine (PCZ) given as a 15-min i.v. infusion was 75 mg/m2. The highest peak plasma PCZ concentration achieved was 1100 ng/ml. The present study was conducted to determine if PCZ levels high enough to block do...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 1994, Vol.34 (5), p.377-384
Hauptverfasser:	SRIDHAR, K. S, KRISHAN, A, SAMY, T. S. A, DUNCAN, R. C, SAUERTEIG, A, MCPHEE, G. V, AUGUSTE, M. E, BENEDETTO, P. W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Chromatography, High Pressure Liquid Combined Modality Therapy Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - antagonists & inhibitors Doxorubicin - pharmacokinetics Drug Administration Schedule Female Half-Life Humans Infusions, Intravenous Male Medical sciences Middle Aged Neoplasms - drug therapy Pharmacology. Drug treatments Prochlorperazine - administration & dosage Prochlorperazine - adverse effects Prochlorperazine - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!